Kate Haviland
Publishing timestamp: 2024-02-28 05:52:01
Summary
Blueprint Medicines CEO, Kate Haviland, achieved FDA approval for the company's treatment of rare disease indolent systemic mastocytosis, expanding the reach of the treatment and increasing revenue. Haviland emphasizes the importance of diversity in the company's success.
Sentiment: POSITIVE
Tickers: BPMC,
Keywords: blueprint medicines corp, media, business news, exclude from automated curation,
Source: https://www.cnbc.com/2024/02/28/kate-haviland-cnbc-changemakers.html